BRIEF-Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial

Reuters
11 Feb
BRIEF-Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial

Feb 11 (Reuters) - Moleculin Biotech MBRX.O:

  • MOLECULIN RECEIVES FIRST COUNTRY APPROVAL IN EUROPE TO BEGIN RECRUITING FOR THE MIRACLE PHASE 3 R/R ACUTE MYELOID LEUKEMIA $(AML.UK)$ PIVOTAL TRIAL

  • MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE TRIAL EXPECTED Q1 2025

Source text: ID:nPn7y6kN7a

Further company coverage: MBRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10